Chimeric HLA Antibody Receptor T Cells to Specifically Eliminate HLA-DQ–Specific B Cells
Authors:
- Carolt AranaCACarolt Arana
- Ilse GilleIGIlse Gille
- Renate HagedoornRHRenate Hagedoorn
- Ainhoa García-BusquetsAGAinhoa García-Busquets
- Hannah C.M. SchenkHSHannah C.M. Schenk
- Sergi BetriuSBSergi Betriu
- Dennis F.G. RemstDRDennis F.G. Remst
- Yvonne J.H. de VaalYVYvonne J.H. de Vaal
- Rico BuchliRBRico Buchli
- Aiko P.J. de VriesAVAiko P.J. de Vries
Open Access
- 3 September 2026
- journal article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Abstract
Key Points: HLA-DQ2/DQ7 chimeric HLA antibody receptor T cells, the first HLA class II chimeric HLA antibody receptor T cells, selectively eliminated cognate HLA-DQ–specific B cells in a dose-dependent manner. HLA-DQ chimeric HLA antibody receptor T cells efficiently depleted HLA-DQ–specific B cells with corresponding specificity in vivo . Chimeric HLA antibody receptor T-cell therapy expanded donor availability through targeted desensitization and represented a potential antigen-specific antibody-mediated rejection therapy. Background: Chimeric antigen receptor T-cell therapy has revolutionized the treatment of hematologic malignancies by effectively eliminating tumor cells. In the field of kidney transplantation, comparable cellular therapies are being explored to facilitate transplantation and prevent graft rejection. Chimeric HLA antibody receptor (CHAR) T cells are a promising therapy for eliminating HLA-specific B cells in sensitized patients and potentially ameliorating antibody-mediated rejection. We previously demonstrated that HLA class I CHAR T cells selectively eliminated HLA class I–specific B cells with high specificity. Since HLA sensitization is most often directed against HLA-DQ of the allograft, we developed HLA-DQ2 and HLA-DQ7 CHAR T cells to target B cells with corresponding HLA specificity. Methods: We designed viral vectors encoding HLA-DQ CHARs composed of HLA-DQA1*05:01 α chain with either HLA-DQB1*02:01 (HLA-DQ2) or HLA-DQB1*03:01 (HLA-DQ7) β chains, class II–associated invariant chain peptide, and intracellular 4-1BB costimulatory and CD3ζ signaling domains. Upon production of HLA-DQ CHAR T cells, we evaluated CHAR expression, cytotoxic activity, production of cytokines and cytotoxic mediators, and sensitivity to immunosuppressive drugs in in vitro models. We further assessed the cytotoxic activity of HLA-DQ CHAR T cells in an immunodeficient mouse model and in primary material from sensitized individuals. Results: CHAR-transduced Jurkat triple parameter reporter cells expressing reporter constructs for T-cell activation markers showed robust activation upon specific stimulation. Primary CD8 + T cells expressing HLA-DQ2 and HLA-DQ7 CHAR molecules specifically eliminated HLA-DQ2– or HLA-DQ7–specific B cells, respectively, and produced interferon gamma, soluble Fas ligand, perforin, and granzyme B. Maintenance immunosuppressive drug regimens initiated at the time of coincubation with target cells had limited effects on CHAR T-cell functionality. Finally, HLA-DQ CHAR T cells effectively eliminated HLA-DQ–specific B cells in an in vivo mouse model, as well as in primary material from sensitized individuals. Conclusions: HLA-DQ2 and HLA-DQ7 CHAR T cells, the first HLA class II CHAR T cells, selectively and effectively eliminated corresponding HLA-DQ–specific B cells in vitro , in vivo , and in primary material from sensitized individuals.Keywords
Funding Information
- Nierstichting (20OI148)
- Nierstichting (23OK2066)
- Fundació Acadèmia de les Ciències Mèdiques i de la Salut de Catalunya i de Balears
- Instituto de Salud Carlos III (PI20/00227)
- Instituto de Salud Carlos III (PI23/00990)
- Redes de Investigación Cooperativa Orientadas a Resultados en Salud and the NextGenerationEU /Mecanismo para la Recuperación y la Resiliencia (RICORS2024)
- Redes de Investigación Cooperativa Orientadas a Resultados en Salud and the NextGenerationEU /Mecanismo para la Recuperación y la Resiliencia (RD21/0005/0003)
- Secretaria d’Universitats i Recerca & CERCA Program del Departament d’Economia i Coneixement de la Generalitat de Catalunya (2021-SGR-01424)
This publication has 50 references indexed in Scilit:
- A multicenter prospective cohort study evaluating impact of an active delisting strategy to enable kidney transplantation in wait-listed candidates with calculated Panel Reactive Antibody ≥ 99.9%Kidney International, 2025
- Anti-HLA serologic response to CD38-targeting desensitization therapy is challenged by peripheral memory B cells in highly sensitized kidney transplant candidatesAmerican Journal of Transplantation, 2024
- CAR T-cell therapy—paving the way for sensitized kidney transplant patientsKidney International, 2024
- Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodiesCell Reports Medicine, 2023
- Specific human leucocyte antigen-DQ risk epitope mismatches are associated with chronic lung allograft dysfunction after lung transplantationAmerican Journal of Transplantation, 2023
- Significance of HLA-DQ in kidney transplantation: time to reevaluate human leukocyte antigen–matching priorities to improve transplant outcomes? An expert review and recommendationsKidney International, 2021
- Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patientsKidney International, 2018
- The 25th anniversary of the Eurotransplant Acceptable Mismatch program for highly sensitized patientsTransplant Immunology, 2015
- Profiling antibodies to class II HLA in transplant patient seraHuman Immunology, 2014
- Naturally processed peptides from HLA-DQ7 (α1*0501-β1*0301): influence of both α and β chain polymorphism in the HLA-DQ peptide binding specificityEuropean Journal of Immunology, 1998